Thompson Davis & Co’s Sonnet BioTherapeutics SONN Stock Holding History

Thompson Davis & Co’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Hold	0	–	-$3K	–	710
2017 Q4	–	Hold	0	–	–	–	586
2017 Q3	–	Hold	0	–	–	–	954
2017 Q2	–	Hold	0	–	–	–	943
2017 Q1	–	Hold	0	–	–	–	944
2016 Q4	–	Hold	0	–	–	–	919
2016 Q3	–	Hold	0	–	–	–	531
2016 Q2	–	Sell	-1	Closed	-$414K	–	119
2016 Q1	$314K	Hold	1	–	–	0.47%	49
2015 Q4	$381K	Hold	1	–	–	0.54%	34
2015 Q3	$396K	Buy	+1	New	+$1.18M	0.55%	35
2015 Q2	–	Hold	0	–	–	–	33
2015 Q1	–	Hold	0	–	–	–	25
2014 Q4	–	Hold	0	–	–	–	45
2014 Q3	–	Hold	0	–	–	–	38
2014 Q2	–	Hold	0	–	–	–	27
2014 Q1	–	Hold	0	–	–	–	10
2013 Q4	–	Hold	0	–	–	–	16

Other funds holding SONN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SCM

Stumpf Capital Management Scottsdale, Arizona $53.8M AUM 43.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Thompson Davis & Co's SONN Position: Q1 2018 in Review

Thompson Davis & Co held its Sonnet BioTherapeutics (SONN) position steady in Q1 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #710.

Thompson Davis & Co first reported a position in SONN in Q3 2015 and has held it in 3 quarters since. The position peaked at $396K in Q3 2015.

Thompson Davis & Co held 0 shares of Sonnet BioTherapeutics worth $0 as of Q1 2018.
Thompson Davis & Co left its Sonnet BioTherapeutics share count unchanged in Q1 2018.
Sonnet BioTherapeutics made up ﹤0.01% of Thompson Davis & Co's portfolio in Q1 2018, its #710 holding.
Thompson Davis & Co first reported a position in Sonnet BioTherapeutics in Q3 2015 and has held it in 3 quarters since.
Thompson Davis & Co's Sonnet BioTherapeutics position peaked at $396K in Q3 2015.

Based on Thompson Davis & Co's 13F filing for Q1 2018, filed 2 May 2018.